Patent Analysis: US 8,623,905 - A Detailed Examination
Summary
U.S. Patent 8,623,905, titled "Combinations of Indole Derivatives," was granted on February 11, 2014, to Eli Lilly and Company. The patent claims combinations of specific indole derivatives, including Compound 1 (identified as LY2835219 or abemaciclib), with other therapeutic agents for treating various cancers, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The patent's prosecution history indicates a focus on combination therapies designed to enhance efficacy and overcome resistance mechanisms. The patent landscape surrounding abemaciclib involves a robust portfolio of patents covering composition of matter, methods of use, and formulations, suggesting a comprehensive strategy to protect the drug's commercial life.
What is the Core Invention of US 8,623,905?
The central inventive concept of US Patent 8,623,905 lies in the synergistic combination of specific indole derivatives, notably abemaciclib (referred to as Compound 1 in the patent), with other active pharmaceutical ingredients for the treatment of cancer. The patent claims not merely the individual compounds but their therapeutic utility when administered in combination. The primary target indications are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, and other solid tumors. The patent asserts that these combinations exhibit enhanced anti-tumor activity compared to monotherapy or other combination regimens.
What are the Key Claims of the Patent?
U.S. Patent 8,623,905 contains several independent and dependent claims detailing the scope of the invention. The most significant claims define the combination therapy itself.
- Claim 1: This independent claim defines a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of an indole derivative of Formula (I) and a therapeutically effective amount of a second therapeutic agent. Formula (I) is defined broadly, but the patent's examples and prosecution history clearly indicate that abemaciclib (Compound 1) is a prime embodiment.
- Claim 2: This claim specifies the indole derivative as being selected from a group including Compound 1. Compound 1 is structurally identified as N-(5-((3-chloro-4-cyanophenyl)amino)-6-methoxy-2-pyrazinyl)-2-fluoro-5-(methylsulfonyl)benzamide, which is abemaciclib.
- Claim 3: This claim further narrows the invention to a combination of Compound 1 and a CDK4/6 inhibitor.
- Claims 4-6: These claims specify the second therapeutic agent to be an aromatase inhibitor, a selective estrogen receptor degrader (SERD), or a GnRH antagonist, respectively.
- Claims 7-12: These claims define specific examples of the second therapeutic agent, including anastrozole, letrozole, fulvestrant, and leuprolide.
- Claims 13-15: These claims pertain to pharmaceutical compositions comprising Compound 1 and a second therapeutic agent.
- Claims 16-19: These claims relate to the use of the combinations for treating specific types of cancer, including HR+, HER2- breast cancer.
The claims emphasize the administration of these compounds in a manner that achieves a therapeutic benefit, often implying a synergistic effect.
What is the Specified Indole Derivative and its Significance?
The specified indole derivative at the heart of this patent is Compound 1, structurally identified as N-(5-((3-chloro-4-cyanophenyl)amino)-6-methoxy-2-pyrazinyl)-2-fluoro-5-(methylsulfonyl)benzamide. This compound is commercially known as abemaciclib.
Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). CDK4 and CDK6 are enzymes that play a crucial role in cell cycle progression, particularly in the G1-to-S phase transition. In many cancers, these kinases are overactive, driving uncontrolled cell proliferation. Abemaciclib, by inhibiting CDK4/6, arrests the cell cycle and induces senescence or apoptosis in cancer cells.
The significance of abemaciclib within the context of US 8,623,905 is its role as a key component of the claimed combination therapies. While abemaciclib itself is covered by other composition of matter patents (e.g., US 8,187,926 B2), this patent specifically protects its use in combination with other agents to enhance anti-cancer efficacy, particularly in breast cancer where endocrine therapy resistance is a major clinical challenge. The combination aims to overcome resistance mechanisms that may arise with single-agent therapy by targeting multiple pathways simultaneously.
What are the Specified Cancer Indications?
The patent explicitly targets the treatment of various cancers, with a primary focus on:
- Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer: This is a significant subtype of breast cancer characterized by the presence of estrogen receptors (ER) and/or progesterone receptors (PR) and the absence of HER2 overexpression. These cancers are often treated with endocrine therapies that target hormone pathways. The combinations claimed in the patent are designed to enhance the efficacy of standard-of-care endocrine therapies, potentially in both early-stage and advanced/metastatic settings.
- Other Solid Tumors: The patent also broadly claims the treatment of "solid tumors" that may benefit from inhibition of cell cycle progression and/or the targeted pathways of the second therapeutic agent.
The specific indications highlight the patent's relevance to major unmet needs in oncology, particularly in the management of breast cancer, a prevalent and complex disease.
What are the Key Combination Agents Mentioned?
US Patent 8,623,905 details several classes of agents that can be combined with the specified indole derivative (abemaciclib). These agents are chosen for their ability to target complementary pathways involved in cancer growth and progression, particularly in endocrine-resistant breast cancer.
The key combination agents include:
- Aromatase Inhibitors: Examples include anastrozole and letrozole. These drugs work by blocking the enzyme aromatase, which converts androgens into estrogens in peripheral tissues, thereby reducing estrogen levels. This is a standard therapy for HR+ breast cancer.
- Selective Estrogen Receptor Degraders (SERDs): Fulvestrant is cited as an example. SERDs bind to the estrogen receptor and promote its degradation, thereby inhibiting estrogen signaling.
- Gonadotropin-Releasing Hormone (GnRH) Antagonists: Leuprolide is mentioned as an example. GnRH antagonists suppress the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the pituitary gland, leading to a decrease in ovarian estrogen production. This is particularly relevant for premenopausal women.
- Other CDK4/6 Inhibitors: While the patent focuses on indole derivatives like abemaciclib, it also contemplates combinations with other CDK4/6 inhibitors, suggesting a broader strategy in targeting this pathway.
The inclusion of these classes of agents underscores the patent's intent to protect combination regimens that enhance the anti-tumor effects of abemaciclib by addressing multiple drivers of cancer cell proliferation and survival.
How Does the Prosecution History Inform the Patent's Scope?
The prosecution history of US Patent 8,623,905 reveals a strategic refinement of claims to overcome prior art and secure broad protection for the claimed combination therapies. Key aspects of the prosecution provide insight into the patent's eventual scope:
- Prior Art Rejection and Amendment: Initial claims may have been rejected based on prior art disclosing individual components or similar combination concepts. Amendments likely focused on clearly defining the synergistic or enhanced therapeutic effect of the specific combinations, differentiating them from existing knowledge.
- Emphasis on Specific Compound and Combinations: The patent office's examination likely focused on the novelty and non-obviousness of combining a specific indole derivative (abemaciclib) with particular classes of agents (aromatase inhibitors, SERDs, GnRH antagonists) for specific indications (HR+ breast cancer).
- Definition of "Therapeutically Effective Amount": The patent likely defines or relies on established definitions of "therapeutically effective amount" to ensure that the claimed methods involve administering sufficient quantities of the drugs to achieve a meaningful clinical outcome.
- Evidence of Efficacy: While not always explicitly detailed in the claims, the prosecution may have involved submission of data demonstrating the efficacy of the claimed combinations, supporting the non-obviousness and utility of the invention.
The history suggests that the patentability hinged on demonstrating that the claimed combinations offered more than simply combining known drugs, likely by highlighting unexpected synergistic benefits or improved outcomes in specific patient populations.
What is the Competitive Patent Landscape for Abemaciclib?
The patent landscape surrounding abemaciclib is extensive and strategically designed to protect its market exclusivity. Eli Lilly and Company has secured a portfolio of patents covering various aspects of the drug:
- Composition of Matter: Foundational patents protect the abemaciclib molecule itself. For example, U.S. Patent 8,187,926 B2, granted to Eli Lilly and Company, covers compounds including abemaciclib and their use in treating proliferative disorders. This patent is crucial for its initial market protection.
- Methods of Use: Patents such as US 8,623,905 focus on specific therapeutic applications, particularly combination therapies. Other method-of-use patents likely cover monotherapy for specific indications, dosing regimens, and treatment of particular patient subgroups.
- Formulations and Delivery: Patents may exist for specific pharmaceutical formulations of abemaciclib (e.g., tablets, capsules), including extended-release formulations or specific excipient combinations that improve bioavailability or patient compliance.
- Manufacturing Processes: While less commonly publicized, patents covering novel or efficient methods of synthesizing abemaciclib could also be part of the portfolio.
- Polymorphs and Salts: For many active pharmaceutical ingredients, patents are sought for different crystalline forms (polymorphs) or salt forms that may offer advantages in stability, solubility, or manufacturing.
The robustness of this patent portfolio indicates a deliberate strategy to maximize the commercial life of abemaciclib by covering its development from molecule to approved therapeutic use and subsequent line extensions. Competitors seeking to enter the market with abemaciclib generics or biosimilars (though abemaciclib is a small molecule, not a biologic) would need to navigate this complex web of intellectual property.
What are the Potential Implications for Market Entry and Generic Competition?
The existence and scope of US Patent 8,623,905, along with other abemaciclib-related patents, have significant implications for market entry and the eventual advent of generic competition.
- Extended Market Exclusivity: Combination patents like US 8,623,905 can extend the period of market exclusivity beyond the expiration of the original composition of matter patents. If abemaciclib is prescribed as part of a combination therapy protected by this patent, generic manufacturers cannot market their product for that specific combination use until this patent expires.
- Blocking Generic Formulations: Even if the composition of matter patent expires, specific formulations or methods of use protected by later-expiring patents can prevent generic entry or limit their approved indications.
- Litigation Risk: Generic manufacturers often challenge the validity or inventiveness of patents. Litigation surrounding abemaciclib patents would be expected, focusing on prior art, obviousness, and enablement.
- Indication-Specific Competition: Generic competition may first emerge for abemaciclib as a monotherapy if the primary composition of matter patent expires and no other patents block that specific use. However, its use in combination therapies, as claimed in US 8,623,905, would likely remain protected for a longer duration.
The effective date of US 8,623,905 is November 11, 2013 (filing date). This patent is listed in the FDA's Orange Book as expiring on November 11, 2033. This date is critical for understanding the period during which abemaciclib use in the specific claimed combinations is protected.
Key Takeaways
- US Patent 8,623,905 protects combination therapies involving abemaciclib (Compound 1) and other agents for treating HR+, HER2- breast cancer and other solid tumors.
- The patent's claims focus on the enhanced therapeutic effect of these specific drug combinations.
- Key combination agents include aromatase inhibitors, SERDs, and GnRH antagonists.
- The patent's prosecution history indicates a strategy to differentiate claimed combinations from prior art through demonstrated therapeutic benefit.
- A comprehensive patent portfolio, including US 8,623,905, surrounds abemaciclib, aimed at extending market exclusivity and shaping generic entry strategies.
- This patent is listed with an expiration date of November 11, 2033, in the FDA's Orange Book.
Frequently Asked Questions
1. What is the expiration date of US Patent 8,623,905?
U.S. Patent 8,623,905 is listed in the FDA's Orange Book with an expiration date of November 11, 2033.
2. Does this patent cover abemaciclib as a monotherapy?
No, this patent specifically covers combination therapies of abemaciclib with other agents. Abemaciclib as a monotherapy is likely covered by other, earlier-expiring composition of matter patents.
3. What specific types of breast cancer are targeted by this patent?
The patent explicitly targets hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
4. Can a generic version of abemaciclib be sold before November 11, 2033?
A generic version could potentially be sold for uses not covered by US 8,623,905 or other active patents. However, its use in the specific combination therapies claimed by this patent would be restricted until its expiration.
5. What is the significance of "synergistic effect" in relation to this patent?
The patent claims combinations that are intended to achieve a therapeutic effect greater than the sum of their individual effects. This synergistic aspect is often a key factor in establishing the patentability and commercial value of combination therapies.
Cited Sources
[1] Eli Lilly and Company. (2014). Combination of indole derivatives (U.S. Patent No. 8,623,905). Washington, DC: U.S. Patent and Trademark Office.
[2] Eli Lilly and Company. (2012). Indole derivatives (U.S. Patent No. 8,187,926 B2). Washington, DC: U.S. Patent and Trademark Office.
[3] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Database] (Note: Specific URL not provided as it is a dynamic database).
